CD40: Lord of the endothelial cell

Blood

Volumn 112, Issue 9, 2008, Pages 3531-3532

  Phipps, Richard P ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; CD40 LIGAND; GAMMA INTERFERON RECEPTOR;

ANTIGEN EXPRESSION; CELL ACTIVATION; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; INNATE IMMUNITY; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS RESISTANCE;

EID: 61849157355     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175034     Document Type: Note

References (7)

1. Banchereau J, Bazan F, Blanchard D, et al. TheCD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
2. Fries KM, Sempowski GD, Phipps RP, et al. CD40 expression by human fibroblasts. Clin Immunol Immunopathol. 1995;77:42-51.
3. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
4. Phipps RP, Koumas L, Kaufman J, et al. The CD40-CD40 ligand system: A potential therapeutic target in atherosclerosis. Curr Opin Invest Drugs. 2001;2:773-777.
5. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;5:591-594.
6. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci. 2006;27:190-194.
7. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100: 158-173.